The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D3

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4402-4409

  Wang, Xuening ^a   Studzinski, George P ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CALCITRIOL; MESSENGER RNA; PROTEIN C JUN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DNA PROTEIN COMPLEX; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LEUKEMIA; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 2; CALCITRIOL; CELL DIFFERENTIATION; HL-60 CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 33646264299     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3109     Document Type: Article

References (51)

1. DeLuca HF. New concepts of vitamin D functions. Ann N Y Acad Sci 1992;669:59-69.
2. Studzinski GP, McLane JA, Uskokovic MR. Crit Rev Eukaryotic Gene Expr 1993;3:279-312.
3. 3 receptor: a network of coactivator interactions. Gene 2000;246:9-21.
4. 3 24-hydroxylase gene. J Biol Chem 1994;269:10545-50.
5. 3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995;1263:1-9.
6. 3 and dietary Ca2+. J Steroid Biochem Mol Biol 2004;89-90:303-8.
7. 3 target genes. Mol Endocrinol 2005;19:2685-95.
8. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 2003;164:29-42.
9. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
10. 3 in promyelocytic NB4 leukemia cells: a structure-function study. Endocrinology 1998;139:457-65.
11. 3-induced differentiation of HL60 cells. J Cell Biochem 2001;80:471-82.
12. Marcinkowska E. Evidence that activation of MEK1,2/erk1,2 signal transduction pathway is necessary for calcitriol-induced differentiation of HL-60 cells. Anticancer Res 2001;21:499-504.
13. 3 in the marine myelomonocytic leukemia cell line WEHI-3. Cancer Res 1986;46:6316-21.
14. Studzinski GP, Bhandal AK, Brelvi ZS. A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol. Proc Soc Exp Biol Med 1985;179:288-95.
15. 3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. J Biol Chem 2002;33:29643-53.
16. 3. J Cell Biochem 2003;89:1087-101.
17. 3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. J Cell Physiol 2005;204:964-74.
18. Coffman FD, Studzinski GP. Differentiation-related mechanisms which suppress DNA replication. Exp Cell Res 1999;248:58-73.
19. Studzinski GP, Harrison LE. Differentiation-related changes in the cell cycle traverse. Int Rev Cytol 1999;189:1-58.
20. Shafarenko M, Liebermann DA, Hoffman B. Egr-1 abrogates the block imparted by c-myc on terminal M1 myeloid differentiation. Blood 2005;3:871-8.
21. Kolla SS, Studzinski GP. Constitutive DNA binding of the low mobility forms of the AP-1 and SP-1 transcription factors in HL60 cells resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res 1994;54:1418-21.
22. Studzinski GP, Wang X, Ji Y, et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem MoL Biol 2005;97:47-55.
23. Davis AF, Meighan-Mantha RL, Riegel AT. Effects of TPA, bryostatin 1, and retinoic acid on PO-B, AP-1, and AP-2 DNA binding during HL-60 differentiation. J Cell Biochem 1997;65:308-24.
24. Wang Y, Prywes R. Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene 2000;19:1379-85.
25. 3. Exp Cell Res 1996;224:312-22.
26. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979;54:713-33.
27. 3. J Natl Cancer Inst 1997;89:1199-206.
28. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990;250:997-1000.
29. Andrews NC, Faller DV. Rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
30. 3 and its analogs. Exp Cell Res 2004;298:339-58.
31. Kim CW, Suh SI, Sung SH, Lee IK, Lee KS. A transcriptional factor decoy against AP-1 suppresses TGF-β1-induced type I collagen gene expression in cultured keloid fibroblasts. J Dermatol Sci 2005;37:49-51.
32. 3: physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol 1976;5 Suppl:151-65S.
33. Miyamoto K, Kesterson RA, Yamamoto H, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997;11:1165-79.
34. 3-induced growth inhibition. J Biol Chem 2002;277:25884-92.
35. 3-induced HL-60 cell differentiation. J Biol Chem 1990;265:15823-31.
36. 3-induced HL-60 cell differentiation. J Biol Chem 1994;269:4070-7.
37. van Dam H, Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001;20:2453-64.
38. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-6.
39. Wagner EF. Functions of AP1 (Fos/Jun) in bone development. Ann Rheum Dis 2002;61 suppl 2:ii40-2.
40. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000;19:2056-68.
41. Passegue E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 2000;19:2969-79.
42. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking jun-B expression in the myeloid lineage. Cell 2001;104:21-32.
43. Datta R, Sherman ML, Stone RM, Kufe D. Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth Differ 1991;2:43-9.
44. Mollinedo F, Naranjo JR. Uncoupled changes in the expression of the jun family members during myeloid cell differentiation. Eur J Biochem 1991;200:483-6.
45. Nakamura T, Datta R, Kharbanda S, Kufe D. Regulation of jun and fos gene expression in human monocytes by the macrophage colony-stimulating factor. Cell Growth Differ 1991;2:267-72.
46. McCabe LR, Kockx M, Lian J, Stein J, Stein G. Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation. Exp Cell Res 1995;218:255-62.
47. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994;226:443-8.
48. Shafarenko M, Amanullah A, Gregory B, Liebermann DA, Hoffman B. Fos modulates myeloid cell survival and differentiation and partially abrogates the c-myc block in terminal myeloid differentiation. Blood 2004;103:4259-67.
49. Sherman ML, Stone RM, Datta R, Bernstein SH, Kufe DW. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem 1990;265:3320-3.
50. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-71.
51. Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 1995;15:3463-9.